Condition: Gulf War Illness · Chronic Fatigue · Neurocognitive Dysfunction · Sponsor: VA Office of Research and Development
The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive deficits.
This description comes directly from the study's public registry record.
Saurabh Chatterjee, PhD · (562) 826-8000 · saurabhc@hs.uci.edu
Jonathan Skupsky · (562) 826-8000 · Jonathan.Skupsky@va.gov
Always discuss trial participation with your own doctor first.
| VA Long Beach Healthcare System, Long Beach, CA | Long Beach, California, United States | Recruiting |
| Miami VA Healthcare System, Miami, FL | Miami, Florida, United States | Recruiting |
| VA Salt Lake City Health Care System, Salt Lake City, UT | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05367245